Biohellenika
Greek stem cell bank founded in 2006 specializing in cord blood, cord tissue, and placenta cryopreservation, complemented by molecular diagnostics (NIPT, paternity, pharmacogenomics) and PRP therapies, serving 50,000+ families across Greece and six international markets.
- Company typePrivate
- Founded2006
- HeadquartersAthens, Greece
- Headcount51–100
- GTM typeB2C
- OfferingServices
What Biohellenika does
Biohellenika is a Greek biotechnology company founded in 2006 in Thessaloniki, specializing in the collection, processing, and long-term cryogenic storage of hematopoietic and mesenchymal stem cells from umbilical cord blood, umbilical cord tissue, and placenta at childbirth. The company also collects Very Small Embryonic-Like Stem Cells (VSELs) from cord blood and operates an in-house molecular laboratory offering non-invasive prenatal testing (NIPT), DNA paternity testing, pharmacogenomics, cardiovascular and thrombosis testing, HPV detection, celiac/lactose intolerance testing, microbiome analysis, and infertility diagnostics. Additional service lines include platelet-rich plasma (PRP) applications in orthopedics, gynecology, and individualized facial skincare, plus a Medical Advisory Center providing consultation to families. The company holds FACT, AABB, ESYD ISO 15189, ISO 9001, and GMP certifications alongside a Greek Ministry of Health operating license, and operates 8 offices across Greece plus international offices in Cyprus, Italy (through wholly-owned subsidiary Bioitaly SRL), Serbia, Bulgaria, North Macedonia, and the Philippines.
The company is led by academic founders — Dr. Georgios Koliakos (Emeritus Professor of Biochemistry, Aristotle University of Thessaloniki) and Dr. Kokkona Kouzi-Koliakou (Emeritus Professor of Histology-Embryology, AUTH) — with deep translational research credentials (202 and 62 publications respectively, h-index 40) and 5 patents in cellular therapy. The company claims to have performed the first therapeutic use of stem cells in Greece in 2009 and reports 50,000+ families served.
Biohellenika generates revenue through a mix of subscription recurring storage fees (annual cadence for long-term cryopreservation) and one-time service fees for NIPT, paternity testing, genetic profiling, and PRP treatments, with a primary customer segment of expectant parents seeking biological insurance for potential future therapeutic use. Distribution is sales-led via direct offices, parent seminars, medical referrals (obstetricians/gynecologists), and the company website, supported by healthcare professional networks across both Greek and international markets. R&D is partially funded through ESPA (EU/Greece) research programs including Proderma and ArthroMicroPerMed for skin regeneration patch development.
Biohellenika firmographics
Firmographics- Name
- Biohellenika
- Legal name
- BIOHELLENIKA ΑΝΩΝΥΜΟΣ ΕΤΑΙΡΙΑ – ΕΤΑΙΡΙΑ ΕΝΤΑΣΗΣ ΓΝΩΣΗΣ – ΜΕΤΑΦΟΡΑΣ ΤΕΧΝΟΓΝΩΣΙΑΣ – ΤΕΧΝΟΛΟΓΙΑΣ – ΒΙΟΤΕΧΝΟΛΟΓΙΑΣ – ΠΑΡΟΧΗΣ ΥΠΗΡΕΣΙΩΝ ΚΑΙ ΣΥΜΒΟΥΛΩΝ
- Website
- https://biohellenika.gr
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Greek stem cell bank founded in 2006 specializing in cord blood, cord tissue, and placenta cryopreservation, complemented by molecular diagnostics (NIPT, paternity, pharmacogenomics) and PRP therapies, serving 50,000+ families across Greece and six international markets.
- Ownership category
- akta.pro rank
Biohellenika industry classification
Industry- Product category
- Stem Cell Banking Services
- NAICS
- Blood and Organ Banks (621991), Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industries
- Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)
Keywords
Where Biohellenika is headquartered
LocationHeadquarters
- HQ city
- Athens
- HQ country
- Greece
- HQ region
- Europe
Offices14 records
Markets served
Biohellenika business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Stem Cell Banking Services: Collection, processing, and long-term cryopreservation of stem cells from cord blood, cord tissue, and placenta at birth. Services include initial processing and annual storage fees.
- Prenatal Testing (NIPT): Non-invasive prenatal testing from maternal blood for detection of chromosomal abnormalities including Down syndrome.
- Molecular Laboratory Services: DNA testing including paternity tests, prenatal paternity, HPV detection, celiac/lactose intolerance testing, genetic profiling, pharmacogenomics, cardiovascular disease testing, microbiome analysis, and infertility diagnostics.
- PRP Treatments: Platelet-rich plasma treatments for orthopedics, gynecology, and aesthetic medicine including individualized facial creams.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Stem Cell Storage Annual Subscription |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Biohellenika product offering
Product offeringCore offering
Biohellenika collects, processes, and cryopreserves hematopoietic and mesenchymal stem cells from umbilical cord blood, cord tissue, and placenta at childbirth, offering long-term storage under FACT and AABB international accreditations. The company also operates a molecular diagnostic laboratory providing NIPT prenatal screening, paternity testing, genetic profiling, pharmacogenomics, HPV detection, karyotyping, and PRP treatments in orthopedics, gynecology, and aesthetics.
Product overview
Biohellenika is a licensed stem cell bank offering a comprehensive portfolio of biological storage and genetic testing services. The core offering is stem cell banking from umbilical cord blood and tissue collected at childbirth, with associated molecular laboratory services including prenatal testing (NIPT), DNA paternity testing, and various genetic analysis tests. Additional services include PRP (platelet-rich plasma) applications for orthopedics, gynecology, and aesthetic medicine, plus a medical consulting center. The company also conducts research through EU-funded programs (Proderma, ArthroMicroPerMed). The product ecosystem centers on cord blood banking with multiple collection methods, supported by an accredited molecular diagnostic laboratory offering genetic testing services, and enhanced by PRP therapeutic applications.
Differentiator
Problem solved
Functional benefit
Products and services
- Cord Blood Stem Cell Banking
- Umbilical Cord Tissue (Mesenchymal) Stem Cell Storage
- VSELs Collection (Very Small Embryonic-Like Stem Cells)
- Second Collection of Umbilical Cord Blood from Placenta
- Non-Invasive Prenatal Test (NIPT)
- DNA Paternity Testing
- Genetic Profile Analysis Genetic profiling test for inherited conditions and predispositions, supporting family health planning and personalized medicine decisions.
- Pharmacogenomics Testing
- Cardiovascular Diseases & Thrombosis Testing
- Prenatal Karyotype Analysis
- Infertility Testing
- HPV Detection
- Celiac Disease & Lactose Intolerance Testing
- Nutritional Test
- PRP in Orthopedics
- PRP in Gynecology
- Individualized PRP Facial Cream
- Medical Advisory Center Consulting
Quantifiable outcome
- 50,000+ families have trusted Biohellenika for stem cell banking services
- +3 more outcomes
Companies that use Biohellenika
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Biohellenika technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Biohellenika partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and regional.
- NANOTYPOS O.E.coreNanoprinting research and development company collaborating on the ArthroMicroPerMed program for development of innovative polymeric patches with antimicrobial activity supplemented with extracellular matrix components and stem cells for skin regeneration.
- Professor Bikiaris Research TeamcoreCollaborating on the ArthroMicroPerMed project for development of advanced polymeric materials for skin regeneration combined with stem cells. The team has necessary experience and appropriate laboratory equipment for development of new advanced polymeric materials.
- Bioitaly SRLregionalInternational subsidiary operation in Italy located in Catania, providing stem cell banking services to the Italian market.
- ESPA (National Strategic Reference Framework)coreCo-funded by Greece and the European Union through ESPA programs for research and development projects including the ArthroMicroPerMed project and Proderma program for innovative skin regeneration patches.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Biohellenika competitors and assessment
Company assessmentBroad incumbents
- ViaCord: US-based family cord blood bank owned by Revvity (formerly PerkinElmer); broad incumbent with global brand recognition and full accreditation stack comparable to Biohellenika.
- Eurofins Genomics: European-wide diagnostic laboratory network offering paternity, NIPT, and genetic testing; broad incumbent that could compete with Biohellenika's molecular laboratory services across SE European markets.
- Cord Blood Registry (CBR): Largest US private cord blood bank, now part of CooperCompanies; provides global scale benchmarking for what Biohellenika could achieve with continued international expansion.
- Natera: Large US-based genetic testing company with Panorama NIPT and broader reproductive health testing portfolio; competes directly with Biohellenika's NIPT/Nativa Test and molecular laboratory service line.
Direct peers
- Vita 34: German private cord blood bank publicly listed; closest EU direct peer with similar subscription model, comparable accreditations, and multi-country presence across Central and SE Europe.
- FamiCord Group: Largest cord blood bank in Europe, operating PBKM (Poland) and FamiCord (Germany) brands with multiple country presence; directly comparable to Biohellenika as a private/family cord blood bank with international expansion and similar AABB/FACT accreditation focus.
- Smart Cells International: UK-headquartered cord blood bank serving international markets; directly comparable service offering with emphasis on VSELs and mesenchymal stem cell storage, similar technology portfolio to Biohellenika.
- Cryo-Save (Esperite): European-headquartered family cord blood bank with operations in multiple countries; direct competitor offering cord blood and cord tissue storage with comparable recurring subscription model and EU consumer-protection compliance.
- Cells4Life: UK-based private cord blood and cord tissue bank with international distribution; competes in the same expectant-parent segment with similar subscription-based service model and cell-processing technology.
Regional players
- StemCord: Singapore-based family cord blood bank with Asia-Pacific focus; comparable service offering with Biohellenika's Philippines presence and provides insight into how Biohellenika could expand in SE Asia.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Biohellenika social profiles
Digital presenceBiohellenika compliance and trust
Trust signalCompliance8 records
Biohellenika financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biohellenika leadership team
Management profileNumber of profiles
Profiles6 records
Biohellenika subsidiaries and ownership
Company hierarchySubsidiaries1 record
Biohellenika funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biohellenika M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biohellenika
What does Biohellenika do?
Biohellenika collects, processes, and cryopreserves hematopoietic and mesenchymal stem cells from umbilical cord blood, cord tissue, and placenta at childbirth, offering long-term storage under FACT and AABB international accreditations. The company also operates a molecular diagnostic laboratory providing NIPT prenatal screening, paternity testing, genetic profiling, pharmacogenomics, HPV detection, karyotyping, and PRP treatments in orthopedics, gynecology, and aesthetics.
Is Biohellenika a public or private company?
Biohellenika is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Biohellenika founded?
Biohellenika was founded in 2006. It employs 51 to 100 people.
Where is Biohellenika based?
Biohellenika is headquartered in Athens, Greece, in the Europe region.
How does Biohellenika make money?
Four revenue lines are on record. Stem Cell Banking Services are the primary driver. The others are prenatal Testing (NIPT), molecular Laboratory Services and PRP Treatments.
Who are Biohellenika's main competitors?
Broad incumbents on record are ViaCord, Eurofins Genomics, Cord Blood Registry (CBR) and Natera. Direct peers are Vita 34, FamiCord Group, Smart Cells International, Cryo-Save (Esperite) and Cells4Life. StemCord is listed as a regional player.
Does Biohellenika have an API?
No public API is recorded for Biohellenika.
What industry is Biohellenika in?
Biohellenika's product category is Stem Cell Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAFAMAH, Genetic & Prenatal Testing Laboratories. Its NAICS code is 621991 and its SIC code is 8071.